CoChat

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The aim of this paper was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials (RCT) which used benzodiazepines (BZD) as a monotherapy versus placebo, antidepressant drugs (AD), or both. METHODS: Keyword searches were conducted for identifying RCT comparing BZD and AD, and/or placebo in the treatment of depression, using electronic databases from their inception up to April 2017. We selected reports of RCT in which BZD were compared to AD and/or placebo in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression. When feasible, data were subjected to meta-analysis. RESULTS: A total of 38 studies met the criteria for inclusion and were then included in the systematic review. Only 1 study concerned a newer AD, fluvoxamine. For the meta-analysis, we submitted data on response rate from 22 RCT, considering BZD versus placebo (8 comparisons) and BZD versus tricyclic antidepressants (TCA) (20 comparisons). There was a lack of significant differences as to response rate between BZD and placebo, as well as between BZD and TCA. Analysis of individual studies disclosed that, in more than half of the studies comparing BZD to TCA and/or placebo, BZD were significantly more effective than placebo and as effective as TCA. CONCLUSIONS: BZD are a therapeutic option in anxious depression and there are no indications that AD are preferable. There is a pressing need for RCT of adequate methodological quality and follow-up comparing BZD to second-generation AD and placebo in anxious depression.

Overview

Integrity signals

Registry

Crossref · 10.1159/000486696

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Cited by

See all 79

Metadata

Authors
Benasi, G., Guidi, J., Offidani, E., Balon, R., Rickels, K., & Fava, G. A.
Affiliations
  • University of Bologna (IT)
  • Pennsylvania State University (US)
  • Wayne State University (US)
  • University of Pennsylvania (US)
  • University at Buffalo, State University of New York (US)
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2018
Volume
87
Issue
2
Pages
65-74
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W2790662831
Cited by
79
References
66
Citations by year
2026: 4 · 2025: 12 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 14 · 2020: 13 · 2019: 14 · 2018: 3
FWCI
1.29
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Psychotherapy and Psychosomatics (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
benzodiazepines, depression, monotherapy, antidepressants, tricyclic antidepressants, anxious depression, placebo comparison, treatment response rate, fluvoxamine, second-generation antidepressants
MeSH terms
Antidepressive Agents, Tricyclic, Benzodiazepines, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. https://app.cochat.ai/papers/10.1159/000486696
The paper
Benasi, G., Guidi, J., Offidani, E., Balon, R., Rickels, K., & Fava, G. A. (2018). Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000486696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.